Patents by Inventor Mark Suter
Mark Suter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9707291Abstract: The invention relates to compositions and methods for inducing a protective immune response against a poxvirus in a human neonate or infant of less than 6 months of age. The invention encompasses administering a single high dose of an MVA to a human neonate or infant of less than 6 months of age, wherein the administration induces protective T- and B-cell responses against a poxvirus in the human neonate or infant.Type: GrantFiled: March 14, 2014Date of Patent: July 18, 2017Assignee: BAVARIAN NORDIC A/SInventors: Cédric Cheminay, Ariane Volkmann, Paul Chaplin, Mark Suter
-
Publication number: 20160030551Abstract: The invention relates to compositions and methods for inducing a protective immune response against a poxvirus in a human neonate or infant of less than 6 months of age. The invention encompasses administering a single high dose of an MVA to a human neonate or infant of less than 6 months of age, wherein the administration induces protective T- and B-cell responses against a poxvirus in the human neonate or infant.Type: ApplicationFiled: March 14, 2014Publication date: February 4, 2016Applicant: Bavarian Nordic A/SInventors: Cédric Cheminay, Ariane Volkmann, Paul Chaplin, Mark Suter
-
Patent number: 8859257Abstract: The present invention provides modified vaccinia virus (VACV) genomes as well as vectors, especially viral vectors comprising the same. The present invention further provides modified vaccinia viruses. The present invention further provides methods for determining the effect of mutations in VACV with regard to competence for replication in certain cell types. The present invention further provides methods of preparing modified vaccinia viruses.Type: GrantFiled: January 28, 2011Date of Patent: October 14, 2014Assignee: Bavarian Nordic A/SInventors: Jürgen Hausmann, Christine Meisinger-Henschel, Mark Suter
-
Patent number: 8372622Abstract: The invention relates inter alia to a method for inducing a long-term protection in an animal against foreign antigens and tumor antigens comprising the step of administering to the animal at least one factor selected from type I interferons and Flt-3, and to a method for inducing a long-term increase of the number of dendritic cells in an animal comprising the step of administering to the animal a factor selected from type I interferon and Flt-3 and to a method of inducing or enhancing the maturation and/or for the activation of the immune system of an animal comprising the step of administering to the animal a factor selected from type I interferon and Flt-3.Type: GrantFiled: January 14, 2011Date of Patent: February 12, 2013Assignee: Bavarian Nordic A/SInventors: Mark Suter, Sabine Vollstedt, Paul Chaplin
-
Publication number: 20120308995Abstract: The present invention provides modified vaccinia virus (VACV) genomes as well as vectors, especially viral vectors comprising the same. The present invention further provides modified vaccinia viruses. The present invention further provides methods for determining the effect of mutations in VACV with regard to competence for replication in certain cell types. The present invention further provides methods of preparing modified vaccinia viruses.Type: ApplicationFiled: January 28, 2011Publication date: December 6, 2012Applicant: Bavarian Nordic A/SInventors: Jürgen Hausmann, Christine Meisinger-Henschel, Mark Suter
-
Publication number: 20110159032Abstract: The invention relates inter alia to a method for inducing a long-term protection in an animal against foreign antigens and tumor antigens comprising the step of administering to the animal at least one factor selected from type I interferons and Flt-3, and to a method for inducing a long-term increase of the number of dendritic cells in an animal comprising the step of administering to the animal a factor selected from type I interferon and Flt-3 and to a method of inducing or enhancing the maturation and/or for the activation of the immune system of an animal comprising the step of administering to the animal a factor selected from type I interferon and Flt-3.Type: ApplicationFiled: January 14, 2011Publication date: June 30, 2011Applicant: BAVARIAN NORDIC A/SInventors: Mark Suter, Sabine Vollstedt, Paul Chaplin
-
Patent number: 7897156Abstract: The invention concerns the use of a virus to increase the number of dendritic cells or their precursor cells in an immunocompromised animal, including a human. The virus is preferably a Modified Vaccinia Virus Ankara which is capable of infecting the cells of a neonatal or prenatal animal, including a human, but not capable of being replicated to infectious progeny virus in the neonatal or prenatal animal, including a human.Type: GrantFiled: May 12, 2008Date of Patent: March 1, 2011Assignee: Bavarian Nordic A/SInventors: Mathias Ackermann, Mark Suter, Hans Peter Hefti, Ruth Hefti, legal representative, Marco Franchini, Sabine Vollstedt, Paul Chaplin
-
Patent number: 7892533Abstract: The invention relates inter alia to a method for inducing a long-term protection in an animal against foreign antigens and tumor antigens comprising the step of administering to the animal at least one factor selected from type I interferons and Flt-3, and to a method for inducing a long-term increase of the number of dendritic cells in an animal comprising the step of administering to the animal a factor selected from type I interferon and Flt-3 and to a method of inducing or enhancing the maturation and/or for the activation of the immune system of an animal comprising the step of administering to the animal a factor selected from type I interferon and Flt-3.Type: GrantFiled: October 28, 2009Date of Patent: February 22, 2011Assignee: Bavarian Nordic A/SInventors: Mark Suter, Sabine Vollstedt, Paul Chaplin
-
Publication number: 20100048683Abstract: The invention relates inter alia to a method for inducing a long-term protection in an animal against foreign antigens and tumor antigens comprising the step of administering to the animal at least one factor selected from type I interferons and Flt-3, and to a method for inducing a long-term increase of the number of dendritic cells in an animal comprising the step of administering to the animal a factor selected from type I interferon and Flt-3 and to a method of inducing or enhancing the maturation and/or for the activation of the immune system of an animal comprising the step of administering to the animal a factor selected from type I interferon and Flt-3.Type: ApplicationFiled: October 28, 2009Publication date: February 25, 2010Inventors: Mark SUTER, Sabine Vollstedt, Paul Chaplin
-
Patent number: 7628980Abstract: The invention relates inter alia to a method for inducing a long-term protection in an animal against foreign antigens and tumor antigens comprising the step of administering to the animal at least one factor selected from type I interferons and Flt-3, and to a method for inducing a long-term increase of the number of dendritic cells in an animal comprising the step of administering to the animal a factor selected from type I interferon and Flt-3 and to a method of inducing or enhancing the maturation and/or for the activation of the immune system of an animal comprising the step of administering to the animal a factor selected from type I interferon and Flt-3.Type: GrantFiled: April 22, 2005Date of Patent: December 8, 2009Assignee: Bavarian Nordic A/SInventors: Mark Suter, Sabine Vollstedt, Paul Chaplin
-
Publication number: 20090104224Abstract: The invention concern the use of a virus for the preparation of a medicament for the vaccination or treatment of a neonatal or prenatal animal, including a human, wherein the virus is capable of infecting the cells of the neonatal or prenatal animal, including a human, but not capable of being replicated to infectious progeny virus in the neonatal or prenatal animal, including a human. The virus is preferably a Modified Vaccinia Virus Ankara. In particular, the invention concerns the vaccination of neonates against infections with viruses belonging to the same virus group than the virus used for vaccination. Moreover, the invention concerns the vaccination of neonates against antigens selected from foreign antigens and tumour antigens, wherein the tumour antigen and/or the foreign antigen are different from the antigens associated with the virus.Type: ApplicationFiled: May 12, 2008Publication date: April 23, 2009Inventors: Mathias Ackermann, Mark Suter, Hans Peter Hefti, Marco Franchini, Sabine Vollstedt, Paul Chaplin
-
Patent number: 7097842Abstract: The invention concerns the use of a virus for the preparation of a medicament for the vaccination, treatment, or protection, of a neonatal or prenatal animal, including a human, wherein the virus is capable of infecting the cells of the neonatal or prenatal animal, including a human, but not capable of being replicated to infectious progeny virus in the neonatal or prenatal animal, including a human. The virus is preferably a Modified Vaccinia Virus Ankara. In particular, the invention concerns the vaccination of neonates against infections with viruses belonging the same virus group as the virus used for vaccination. Moreover, the invention concerns the vaccination of neonates against antigens selected from foreign antigens and tumor antigens, wherein the tumor antigen and/or the foreign antigen are different from the antigens associated with the virus.Type: GrantFiled: April 18, 2003Date of Patent: August 29, 2006Assignee: Bavarian Nordic A/SInventors: Mark Suter, Sabine Vollstedt, Paul Chaplin
-
Publication number: 20060127984Abstract: The invention concern the use of a virus for the preparation of a medicament for the vaccination or treatment of a neonatal or prenatal animal, including a human, wherein the virus is capable of infecting the cells of the neonatal or prenatal animal, including a human, but not capable of being replicated to infectious progeny virus in the neonatal or prenatal animal, including a human. The virus is preferably a Modified Vaccinia Virus Ankara. In particular, the invention concerns the vaccination of neonates against infections with viruses belonging to the same virus group than the virus used for vaccination. Moreover, the invention concerns the vaccination of neonates against antigens selected from foreign antigens and tumour antigens, wherein the tumour antigen and/or the foreign antigen are different from the antigens associated with the virus.Type: ApplicationFiled: January 27, 2006Publication date: June 15, 2006Applicant: BAVARIAN NORDIC A/SInventors: Mathias Ackermann, Mark Suter, Hans Hefti, Marco Franchini, Sabine Vollstedt, Paul Chaplin
-
Publication number: 20050260156Abstract: The invention relates inter alia to a method for inducing a long-term protection in an animal against foreign antigens and tumor antigens comprising the step of administering to the animal at least one factor selected from type I interferons and Flt-3, and to a method for inducing a long-term increase of the number of dendritic cells in an animal comprising the step of administering to the animal a factor selected from type I interferon and Flt-3 and to a method of inducing or enhancing the maturation and/or for the activation of the immune system of an animal comprising the step of administering to the animal a factor selected from type I interferon and Flt-3.Type: ApplicationFiled: April 22, 2005Publication date: November 24, 2005Inventors: Mark Suter, Sabine Vollstedt, Paul Chaplin
-
Publication number: 20030224018Abstract: The invention concerns the use of a virus for the preparation of a medicament for the vaccination, treatment, or protection, of a neonatal or prenatal animal, including a human, wherein the virus is capable of infecting the cells of the neonatal or prenatal animal, including a human, but not capable of being replicated to infectious progeny virus in the neonatal or prenatal animal, including a human. The virus is preferably a Modified Vaccinia Virus Ankara.Type: ApplicationFiled: April 18, 2003Publication date: December 4, 2003Applicant: BAVARIAN NORDIC A/SInventors: Mathias Ackermann, Mark Suter, Hans Peter Hefti, Marco Franchini, Sabine Vollstedt, Paul Chaplin
-
Patent number: 6573090Abstract: The present invention relates to an enhanced and simplified herpes virus amplicon packaging system. The packaging system comprises a herpes virus amplicon vector and a packaging vector. In one embodiment, the packaging vector comprises a bacterial artificial chromosome (BAC) containing the HSV-1 genome. The packaging vector contains an intact pac site but is otherwise rendered packaging defective. The packaging vector can be rendered packaging defective by inserting nucleotides into the pac site, or by otherwise interfering with the capsid's ability to close, for example, by increasing the size of the DNA fragment upon which the herpes virus genome is cloned. This system can be used to package a wide range of nucleotide sequences (e.g., a therapeutic or antigenic gene) into an empty herpes virus particle taking advantage of the large transgene capacity of herpes viruses. This system can also be used as a vaccine to induce protective immunity against HSV-1, or other complex pathogens.Type: GrantFiled: December 9, 1999Date of Patent: June 3, 2003Assignees: The General Hospital Corporation, University Medical Centre St. Radboud of the University of Nijmegen, University of Zurich, The Walter & Eliza Hall Institute of Medical ResearchInventors: Xandra O. Breakefield, E. Antonio Chiocca, Yoshinaga Saeki, Cornel Fraefel, Kurt Tobler, Mathias Ackermann, Mark Suter, Gosse J. Adema, Ken Shortman